Navigation Links
Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
Date:9/17/2011

THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women with low bone mass or osteoporosis was associated with a continued increase in bone mineral density (BMD), an important determinant of bone strength, and a persistent reduction in markers of bone turnover. The data were presented at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in San Diego.

Results of the Phase 2 study extension showed that for postmenopausal women with low bone mass or osteoporosis who received up to eight years of continued treatment with Prolia, BMD at the lumbar spine and total hip increased on average by 16.8 percent and 6.9 percent as compared to baseline, respectively.  The overall adverse event profile is consistent with events previously reported.

"We don't yet have a cure for osteoporosis, and many postmenopausal women with this condition who are at high risk for fractures require long-term therapy for this serious disease," said lead author Michael McClung, M.D., founding director, Oregon Osteoporosis Center. "This study provides additional data that Prolia continues to increase bone mineral density progressively over a treatment period of eight years. This study supports the long-term clinical experience of Prolia for women with this chronic condition."

This Phase 2 study extension sought to determine the effects of up to eight years of continued treatment with Prolia on BMD and bone turnover markers in postmenopausal women with low bone mass or osteoporosis.

In the original Phase 2 dose-ranging trial for Prolia, 412 postmenopausal women with a BMD T-score (amount of matter per cubic centimeter of bones) between -1.8 and -4.0 (lumbar spine) and/or -1.8 and -3.5 (total hip or femoral ne
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
2. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
3. XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
4. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
5. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
6. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
7. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
8. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
9. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
10. Vantage Health Announces That All of Its Required Tanzanian Registrations, Permits and Licenses Have Been Formally Issued, Simultaneous With Official Notification That Its Application for Phase One Evaluation of Its HIV Screening Test Kits Has Been
11. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 DePuy ... agreement with Radlink, Inc., an emerging global leader ... image guidance with its hip replacement systems. The ... to help improve patient outcomes, increase patient satisfaction ... with the 81st annual meeting of the American ...
(Date:3/26/2015)... CAMBRIDGE, Mass. , March 26, 2015 ... today announced that it will present preclinical ... pipeline at the 2015 American Association for ... April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia. The ... antibody engineering and nanoliposomal technology platforms, as ...
(Date:3/26/2015)... SANTA CLARA , Kalifornien, 26. März ... neue Veranstaltung Cellworld 2015, die sich speziell ... Bioprozesstechnologien richtet, an. Die zweitägige ... bis 22. September 2015 im Hyatt Regency ... statt. In diesem Forum werden führende ...
Breaking Medicine Technology:DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 2DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 3Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting 2Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting 3Finesse Solutions kündigt Cellworld 2015 an 2
(Date:3/26/2015)... 26, 2015 BioPlus Specialty ... innovative specialty pharmacies, announces the promotion of Sharon ... President of Pharmaceutical Relations. In this position, Ferrer ... our pharmaceuticals partners and providing key leadership in ... BioPlus’ expansion. , “Over the past seven ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 The ... the Patients’ Access to Treatments Act (PATA) that ... week by Reps. David B. McKinley (R-WV) and ... limit cost-sharing requirements for medications placed in a ... by reducing patients’ out-of-pocket expenses. , This legislation ...
(Date:3/26/2015)... Documentation topped the list of ... Living facilities during 2014, despite the introduction of ... The survey queried Administrators, Directors of Nursing, ... and the variety of other interested parties who ... http://www.harmony-healthcare.com ) or participate in the company’s many ...
(Date:3/26/2015)... CRN International took the podium this week at ... achievement of jobseekers from five statewide locations as part ... , The program, called Platform to Employment and being ... the Connecticut Department of Labor, takes active steps to ... them at appropriate companies. CRN, a 40-year-old radio marketing ...
(Date:3/26/2015)... 2015 Zane Benefits, the leader in ... new eBook, “The Comprehensive Guide To Interviewing For Your ... the most important aspect of the hiring process. Many ... the right way, possibly resulting in thousands of dollars ... undertaking, yet it’s essential to the success of your ...
Breaking Medicine News(10 mins):Health News:BioPlus Specialty Pharmacy Expands Executive Team with New Position, Naming Sharon Ferrer as Vice President of Pharmaceutical Relations 2Health News:Pulmonary Hypertension Association Part of Coalition Supporting the Patients’ Access to Treatments Act 2Health News:Harmony Healthcare International Releases 2015 Post Acute Care Trends Report 2Health News:Harmony Healthcare International Releases 2015 Post Acute Care Trends Report 3Health News:CRN International Shows Support For Groundbreaking Connecticut Program To Aid The Unemployed 2Health News:Zane Benefits Announces: New eBook: The Comprehensive Guide To Interviewing For Your Small Business 2
... to Decrease Growing Global Breast ... Cancer Incidence, Mortality Rates, WASHINGTON, March ... Susan G. Komen for the Cure (R) Global Promise Fund ... life-saving,work and outline its new strategy of funding culturally sensitive,sustainable ...
... Corporation (Nasdaq: PRSC ) today announced that it ... its common stock on Form S-3,with the Securities and ... the proposed shelf registration statement immediately,following the filing of ... Ended,December 31, 2007; however, it has no immediate plans ...
... March 12 With the cost of,medical ... Deloitte Center for Health,Solutions finds that better ... can dramatically improve care and drastically reduce,cost., ... Enabled Care at Home,",( http://www.deloitte.com/us/connectedcareathome ) promotes ...
... /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. (TSX: PMD; ... it has completed its previously announced debenture financing ... Ltd. The gross proceeds of the financing totaled ... corporate expenses, with a,focus on the Company,s appeal ...
... for arthritis pain or other conditions while taking aspirin ... aspirins ability to act as an anti-platelet agent, researchers ... a cohort of patients seen by physicians at two ... identified as taking both aspirin and ibuprofen (a nonsteroidal ...
... Lighthouse International has been is,a leader in serving people ... -- for 103 years., People who are legally blind ... the proper education and training., The news that Lt. ... sends an important message that people with vision loss can,achieve ...
Cached Medicine News:Health News:First Lady Laura Bush Joins Susan G. Komen for the Cure (R) to Launch Global Promise Fund Assisting Women Worldwide 2Health News:First Lady Laura Bush Joins Susan G. Komen for the Cure (R) to Launch Global Promise Fund Assisting Women Worldwide 3Health News:Providence Service Corporation Announces Intent to File a Common Stock Shelf Registration Statement 2Health News:Deloitte's 'Connected Care' Model Promotes Technologically Enabled In-Home Health Care, Projects Future Health Care Savings in the Billions 2Health News:Deloitte's 'Connected Care' Model Promotes Technologically Enabled In-Home Health Care, Projects Future Health Care Savings in the Billions 3Health News:PreMD Inc. Completes Debenture Financing 2Health News:PreMD Inc. Completes Debenture Financing 3Health News:Ibuprofen destroys aspirin's positive effect on stroke risk 2Health News:Ibuprofen destroys aspirin's positive effect on stroke risk 3
Plus cylinders only trial lens set....
Magnets move the color disks, Protects Disks from fingerprints, Keeps all the disks in one place, Clear glass insures accurate color perception, Makes Color testing fun....
Opti-Free Express multi-purpose disinfecting solution lasting comfort No Rub formula provides triple action protection for your contact lenses....
Grafton Trial Frame...
Medicine Products: